Dapagliflozin

The benefits of dapagliflozin remain consistent in patients with chronic kidney disease, with and without type 2 diabetes, independent of baseline CV status, according to an analysis of the DAPA-CKD trial.

In a video, Linda F. Fried, MD, MPH, FASN, of University of Pittsburgh, VA Pittsburgh Healthcare System, and co-chair of ASN Kidney Week Education Committee, discussed results of a subanalysis from the DAPA-CKD trial presented at ASN Kidney Week.

Patients with heart failure and reduced ejection fraction who were randomized to dapagliflozin had half the risk of moderate to severe hyperkalemia vs. placebo, according to results of the DAPA-HF trial presented at ASN Kidney Week.

Dapagliflozin reduced the worsening of kidney function and the risk of cardiovascular or renal death in patients with chronic kidney disease irrespective of the underlying cause of kidney disease, according to recently presented data.

In recent years, cardiologists, endocrinologists and primary care physicians have observed marked advances in the use of genetics, artificial intelligence and SGLT2 inhibitors in cardiometabolic care, according to a keynote speech.

The European Society of Cardiology Congress was, for the first time, held virtually. From Aug. 29 to Sept. 1, the digital experience drew virtual attendees from around the world, to watch and hear the latest on topics ranging from the benefits of SGLT2 inhibition in patients without diabetes to the first randomized trial on the question of whether to stop ACE inhibitors and angiotensin receptor blockers in patients with COVID-19.

The FDA granted breakthrough therapy designation to the SGLT2 inhibitor dapagliflozin for adults with chronic kidney disease with and without type 2 diabetes, according to an industry press release.

Treatment with dapagliflozin significantly reduced renal failure, cardiovascular death or hospitalization for heart failure, and prolonged survival among adults with chronic kidney disease with and without type 2 diabetes, study data show.

Healio and Cardiology Today have compiled a list of the most-read news from the virtual European Society of Cardiology Congress.

In the DAPA-CKD trial, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening renal function and death due to CVD or renal disease in patients with chronic kidney disease, both with and without type 2 diabetes.